[go: up one dir, main page]

RU2010129685A - Предупреждение оппортунистических инфекций у индивидуумов с нарушенным иммунитетом - Google Patents

Предупреждение оппортунистических инфекций у индивидуумов с нарушенным иммунитетом Download PDF

Info

Publication number
RU2010129685A
RU2010129685A RU2010129685/15A RU2010129685A RU2010129685A RU 2010129685 A RU2010129685 A RU 2010129685A RU 2010129685/15 A RU2010129685/15 A RU 2010129685/15A RU 2010129685 A RU2010129685 A RU 2010129685A RU 2010129685 A RU2010129685 A RU 2010129685A
Authority
RU
Russia
Prior art keywords
composition according
probiotic
composition
bifidobacterium
opportunistic infections
Prior art date
Application number
RU2010129685/15A
Other languages
English (en)
Other versions
RU2486910C2 (ru
Inventor
Норберт ШПРЕНГЕР (CH)
Норберт ШПРЕНГЕР
Original Assignee
Нестек С.А. (Ch)
Нестек С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39111664&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2010129685(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Нестек С.А. (Ch), Нестек С.А. filed Critical Нестек С.А. (Ch)
Publication of RU2010129685A publication Critical patent/RU2010129685A/ru
Application granted granted Critical
Publication of RU2486910C2 publication Critical patent/RU2486910C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745Bifidobacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

1. Композиция, подходящая для применения в предупреждении оппортунистических инфекций у индивидуумов с нарушенным иммунитетом, содержащая пробиотик Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium breve или Bifidobacterium longum и фукозилированный олигосахарид, выбираемый из группы, состоящей из 2'-фукозиллактозы, 3'-фукозиллактозы, дифукозиллактозы, лакто-N-фукопентаозы, лакто-N-фукогексаозы, фукозиллакто-N-гексаозы и фукозиллакто-N-неогексаозы. ! 2. Композиция по п.1, в которой фукозилированным олигосахаридом является 2'-фукозиллактоза. ! 3. Композиция по п.1 или 2, в которой пробиотиком является Bifidobacterium lactis CNCM 1-3446 или Bifidobacterium longum АТСС BAA-999. ! 4. Композиция по п.1, которая является детской смесью. ! 5. Композиция по п.4, которая содержит от 0,1 до 3 г фукозилированного олигосахарида на 100 г композиции. ! 6. Композиция по п.4 или 5, которая содержит от 103 до 1012 КОЕ пробиотика на 1 г детской смеси. ! 7. Композиция по п.5, которая содержит от 106 до 109 КОЕ пробиотика на 1 г детской смеси. ! 8. Композиция по п.5, которая дополнительно содержит по меньшей мере один пребиотик в количестве от 0,3 до 19 мас.% от композиции. ! 9. Композиция по п.1, которая является биологически активной добавкой и которая содержит в разовой дозе от 0,1 до 3 г фукозилированного олигосахарида и от 105 до 1012 КОЕ пробиотика. ! 10. Применение композиции по любому из пп.1-9 в производстве лекарственных средств или терапевтической питательной композиции для предупреждения оппортунистических инфекций у индивидуумов с нарушенным иммунитетом. ! 11. Применение по п.10, в котором возбудителем оппортунистической инфекции является Pseudomonas aeroginosa. ! 12. Применение по п.10, в котором инфекция, возбуждаемая Pseudomonas aeroginosa, явл�

Claims (12)

1. Композиция, подходящая для применения в предупреждении оппортунистических инфекций у индивидуумов с нарушенным иммунитетом, содержащая пробиотик Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium breve или Bifidobacterium longum и фукозилированный олигосахарид, выбираемый из группы, состоящей из 2'-фукозиллактозы, 3'-фукозиллактозы, дифукозиллактозы, лакто-N-фукопентаозы, лакто-N-фукогексаозы, фукозиллакто-N-гексаозы и фукозиллакто-N-неогексаозы.
2. Композиция по п.1, в которой фукозилированным олигосахаридом является 2'-фукозиллактоза.
3. Композиция по п.1 или 2, в которой пробиотиком является Bifidobacterium lactis CNCM 1-3446 или Bifidobacterium longum АТСС BAA-999.
4. Композиция по п.1, которая является детской смесью.
5. Композиция по п.4, которая содержит от 0,1 до 3 г фукозилированного олигосахарида на 100 г композиции.
6. Композиция по п.4 или 5, которая содержит от 103 до 1012 КОЕ пробиотика на 1 г детской смеси.
7. Композиция по п.5, которая содержит от 106 до 109 КОЕ пробиотика на 1 г детской смеси.
8. Композиция по п.5, которая дополнительно содержит по меньшей мере один пребиотик в количестве от 0,3 до 19 мас.% от композиции.
9. Композиция по п.1, которая является биологически активной добавкой и которая содержит в разовой дозе от 0,1 до 3 г фукозилированного олигосахарида и от 105 до 1012 КОЕ пробиотика.
10. Применение композиции по любому из пп.1-9 в производстве лекарственных средств или терапевтической питательной композиции для предупреждения оппортунистических инфекций у индивидуумов с нарушенным иммунитетом.
11. Применение по п.10, в котором возбудителем оппортунистической инфекции является Pseudomonas aeroginosa.
12. Применение по п.10, в котором инфекция, возбуждаемая Pseudomonas aeroginosa, является инфекцией дыхательных, мочевых или желудочно-кишечного путей.
RU2010129685/15A 2007-12-17 2008-12-05 Предупреждение оппортунистических инфекций у индивидуумов с нарушенным иммунитетом RU2486910C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07123390.2 2007-12-17
EP07123390A EP2072052A1 (en) 2007-12-17 2007-12-17 Prevention of opportunistic infections in immune-compromised subjects
PCT/EP2008/066850 WO2009077352A1 (en) 2007-12-17 2008-12-05 Prevention of opportunistic infections in immune-compromised subjects

Publications (2)

Publication Number Publication Date
RU2010129685A true RU2010129685A (ru) 2012-01-27
RU2486910C2 RU2486910C2 (ru) 2013-07-10

Family

ID=39111664

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010129685/15A RU2486910C2 (ru) 2007-12-17 2008-12-05 Предупреждение оппортунистических инфекций у индивидуумов с нарушенным иммунитетом

Country Status (18)

Country Link
US (2) US9217133B2 (ru)
EP (2) EP2072052A1 (ru)
CN (1) CN101909644A (ru)
AU (1) AU2008337646B2 (ru)
BR (1) BRPI0820837A2 (ru)
CA (1) CA2709396A1 (ru)
ES (1) ES2576642T3 (ru)
IN (1) IN2010DE04311A (ru)
MX (1) MX2010006690A (ru)
MY (1) MY185938A (ru)
PH (1) PH12010501367B1 (ru)
PL (1) PL2234627T3 (ru)
PT (1) PT2234627T (ru)
RU (1) RU2486910C2 (ru)
SG (1) SG186657A1 (ru)
UA (1) UA102830C2 (ru)
WO (1) WO2009077352A1 (ru)
ZA (1) ZA201005088B (ru)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7871785B2 (en) 2007-09-07 2011-01-18 Children's Hospital Medical Center Use of secretor, Lewis and sialyl antigen levels in clinical samples as predictors of risk for disease
EP2072052A1 (en) 2007-12-17 2009-06-24 Nestec S.A. Prevention of opportunistic infections in immune-compromised subjects
EP2451462B1 (en) 2009-07-06 2017-09-06 Children's Hospital Medical Center Inhibiting inflammation with milk oligosaccharides
ES2989649T3 (es) * 2009-07-15 2024-11-27 Nutricia Nv Mezcla de oligosacáridos no digeribles para estimular el sistema inmunitario
EP2813230A1 (en) 2009-07-15 2014-12-17 N.V. Nutricia Fucosyllactose as breast milk identical non-digestible oligosaccharide for treating and/or preventing infections
US9457077B2 (en) 2009-11-18 2016-10-04 Katherine Rose Kovarik Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases
US9408880B2 (en) 2013-12-20 2016-08-09 Katherine Rose Kovarik Method and system for prevention and treatment of allergic and inflammatory diseases
US9585920B2 (en) 2011-02-04 2017-03-07 Katherine Rose Kovarik Method and system for treating cancer cachexia
CN102946742A (zh) * 2010-04-27 2013-02-27 N·V·努特里奇亚 人乳寡糖在婴儿营养物中的用途
WO2011136637A1 (en) * 2010-04-27 2011-11-03 N.V. Nutricia Use of human milk oligosaccharides in infant nutrition
CA2798675A1 (en) 2010-06-01 2011-12-08 Glycom A/S Polymorphs of 2'-o-fucosyllactose and producing thereof
EP2465509A1 (en) * 2010-11-23 2012-06-20 Nestec S.A. Oligosaccharide composition for treating acute respiratory tract infections
EP2455387A1 (en) * 2010-11-23 2012-05-23 Nestec S.A. Oligosaccharide mixture and food product comprising this mixture, especially infant formula
EP2465508A1 (en) * 2010-11-23 2012-06-20 Nestec S.A. Composition comprising hydrolysed proteins and oligosaccharides for treating skin diseases
EP2658547A1 (en) 2010-12-31 2013-11-06 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
US11337990B2 (en) * 2010-12-31 2022-05-24 Abbott Laboratories Human milk oligosaccharides to promote growth of beneficial bacteria
EP3338784B1 (en) 2010-12-31 2020-07-22 Abbott Laboratories Human milk oligosaccharides for modulating inflammation
MX356994B (es) 2010-12-31 2018-06-22 Abbott Lab Composiciones nutricionales que comprenden los oligosacaridos de leche humana y los nucleotidos y los usos de las mismas para tratar y/o prevenir la infeccion viral enterica.
SG191799A1 (en) 2010-12-31 2013-08-30 Abbott Lab Nutritional formulations including human milk oligosaccharides and long chain polyunsaturated polyunsaturated fatty acids and uses thereof
DK2658549T3 (da) * 2010-12-31 2020-06-29 Abbott Lab Fremgangsmåder til reduktion af incidensen af oxidativt stress under anvendelse af humane mælkeoligosaccharider, vitamin c og anti-inflammatoriske midler
US20120171166A1 (en) * 2010-12-31 2012-07-05 Abbott Laboratories Synbiotic combination of probiotic and human milk oligosaccharides to promote growth of beneficial microbiota
MY166946A (en) 2010-12-31 2018-07-25 Abbott Lab Methods of using human milk oligosaccharides for improving airway respiratory health
US10687975B2 (en) 2011-02-04 2020-06-23 Joseph E. Kovarik Method and system to facilitate the growth of desired bacteria in a human's mouth
US11357722B2 (en) 2011-02-04 2022-06-14 Seed Health, Inc. Method and system for preventing sore throat in humans
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US11419903B2 (en) 2015-11-30 2022-08-23 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US9730967B2 (en) 2011-02-04 2017-08-15 Katherine Rose Kovarik Method and system for treating cancer cachexia
US10245288B2 (en) 2011-02-04 2019-04-02 Joseph E. Kovarik Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
US10010568B2 (en) 2011-02-04 2018-07-03 Katherine Rose Kovarik Method and system for reducing the likelihood of a spirochetes infection in a human being
US10583033B2 (en) 2011-02-04 2020-03-10 Katherine Rose Kovarik Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US11273187B2 (en) 2015-11-30 2022-03-15 Joseph E. Kovarik Method and system for reducing the likelihood of developing depression in an individual
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US10086018B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US10835560B2 (en) 2013-12-20 2020-11-17 Joseph E. Kovarik Reducing the likelihood of skin cancer in an individual human being
US10085938B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for preventing sore throat in humans
US11191665B2 (en) 2011-02-04 2021-12-07 Joseph E. Kovarik Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US11523934B2 (en) 2011-02-04 2022-12-13 Seed Health, Inc. Method and system to facilitate the growth of desired bacteria in a human's mouth
US10548761B2 (en) 2011-02-04 2020-02-04 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US10111913B2 (en) 2011-02-04 2018-10-30 Joseph E. Kovarik Method of reducing the likelihood of skin cancer in an individual human being
US9987224B2 (en) 2011-02-04 2018-06-05 Joseph E. Kovarik Method and system for preventing migraine headaches, cluster headaches and dizziness
US10314865B2 (en) 2011-02-04 2019-06-11 Katherine Rose Kovarik Method and system for treating cancer and other age-related diseases by extending the healthspan of a human
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US10842834B2 (en) 2016-01-06 2020-11-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
PH12013501501A1 (en) * 2011-02-10 2019-10-07 Nestec Sa Modulation of growth of bifidobacteria using a combination of oligosaccharides found in human milk
JP6129821B2 (ja) * 2011-05-13 2017-05-17 グリコシン リミテッド ライアビリティー カンパニー プレバイオティクスとしての、精製された2’−フコシルラクトース、3−フコシルラクトース、およびラクトジフコテトラオースの使用
DK3366143T3 (da) 2011-06-20 2025-01-27 Heinz Co Brands H J Llc Probiotiske sammensætninger og fremgangsmåder
CN103813796A (zh) 2011-07-22 2014-05-21 雅培制药有限公司 用于预防胃肠道损伤和/或促进胃肠道修复的低聚半乳糖
CA2846603A1 (en) 2011-08-29 2013-03-07 Abbott Laboratories Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
CN103889240B (zh) * 2011-10-18 2016-09-14 雀巢产品技术援助有限公司 用于增加胰岛素敏感性和/或降低胰岛素抵抗性的组合物
BR112014008425A2 (pt) * 2011-10-18 2017-04-11 Nestec Sa composição para o uso na promoção de angiogênese intestinal e de absorção de nutriente e de tolerância a alimentação enteral e/ou na prevenção e/ou no tratamento de inflamação intestinal e/ou na recuperação após a lesão e a cirurgia intestinal
CN104780932A (zh) 2012-02-29 2015-07-15 伊西康内外科公司 微生物区系的组合物及与其相关的方法
SG11201406022YA (en) * 2012-03-27 2014-10-30 Abbott Lab Methods for modulating cell-mediated immunity using human milk oligosaccharides
DK2708145T3 (en) * 2012-09-14 2016-07-18 Abbott Lab Nutritional Compositions for Use in Methods to Modulate Corticosterone Levels in Psychologically Stressed Individuals
WO2014130789A1 (en) 2013-02-21 2014-08-28 Children's Hospital Medical Center Use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease
US10165788B2 (en) * 2013-06-17 2019-01-01 The Regents Of The University Of California Methods and compositions for improved digestion of milk oligosaccharides
EP2815757A1 (en) * 2013-06-17 2014-12-24 Hestia Investments Composition for topical use in prevention and treatment of bacterial and fungal infections of skin and mucosa
WO2015071402A1 (en) 2013-11-15 2015-05-21 Nestec S.A. Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants and young children
AU2014350144B2 (en) * 2013-11-15 2019-11-21 Société des Produits Nestlé S.A. Compositions for use in the prevention or treatment of URT infections in infants or young children at risk
MX2016006220A (es) 2013-11-15 2016-08-08 Nestec Sa Composiciones para usar en la prevencion o tratamiento de la enterocolitis necrotizante en infantes y niños pequeños nacidos por cesarea.
US10568896B2 (en) 2013-11-19 2020-02-25 Abbott Laboratories Methods for preventing or mitigating acute allergic responses using human milk oligosaccharides
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US12318377B2 (en) 2013-12-20 2025-06-03 Seed Health, Inc. Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
HK1231398A1 (zh) 2014-04-08 2017-12-22 Abbott Laboratories 使用人乳寡糖增强对病原体的粘膜先天免疫反应和/或检测的方法
CN114376234A (zh) 2014-10-24 2022-04-22 进化生物系统股份有限公司 活化的双歧杆菌及其应用方法
EP4529950A3 (en) 2014-10-31 2025-08-20 Pendulum Therapeutics, Inc. Methods and compositions relating to microbial treatment
WO2016086151A1 (en) * 2014-11-26 2016-06-02 Abbott Laboratories Infant formula with rrr-alpha-tocopherol, 2'-fucosyllactose, and a probiotic
US10835544B2 (en) 2014-12-08 2020-11-17 Glycom A/S Synthetic composition for regulating satiety
US10881674B2 (en) 2014-12-08 2021-01-05 Glycom A/S Synthetic composition for treating metabolic disorders
US10987368B2 (en) 2014-12-08 2021-04-27 Glycom A/S Synthetic composition for preventing or treating CVD
CN107427054A (zh) 2015-03-05 2017-12-01 雀巢产品技术援助有限公司 用于预防或治疗婴儿或幼儿的耳炎或支气管炎的组合物
WO2016138911A1 (en) 2015-03-05 2016-09-09 Glycom A/S Composition and method for treating acute respiratory tract infections
US10821124B2 (en) * 2015-03-05 2020-11-03 Societe Des Produits Nestle S.A. Compositions for use in improving stool consistency or frequency in infants or young children
FI3264923T3 (fi) 2015-03-05 2023-04-21 Nestle Sa Koostumuksia käytettäväksi ruoansulatuskanavan infektioiden ehkäisemisessä tai hoitamisessa imeväisillä tai nuorilla lapsilla
US10857167B2 (en) 2015-04-28 2020-12-08 Children's Hospital Medical Center Use of oligosaccharide compositions to enhance weight gain
SG11201807809XA (en) 2016-03-11 2018-10-30 Evolve Biosystems Inc A transient commensal microorganism for improving gut health
EP3471562A4 (en) * 2016-06-15 2020-07-29 Glycom A/S Synthetic compositions comprising human milk oligosaccharides for use the prevention and treatment of disorders
WO2019031961A1 (en) 2017-08-11 2019-02-14 N.V. Nutricia OLIGOSACCHARIDE OF HUMAN MILK TO IMPROVE PHYSICAL IMMUNE CONDITION
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
EP3583858A1 (en) * 2018-06-20 2019-12-25 DuPont Nutrition Biosciences ApS Compositions for treating or preventing gut barrier dysfunction
WO2019229711A1 (en) * 2018-05-31 2019-12-05 Glycom A/S Mixture of hmos for treating autoimmune diseases
WO2020018949A2 (en) 2018-07-19 2020-01-23 Pendulum Therapeutics, Inc. Methods and compositions for microbial engraftment
EP3981256A4 (en) * 2019-06-05 2023-01-25 Morinaga Milk Industry Co., Ltd. COMPOSITION
US12364721B2 (en) 2019-09-24 2025-07-22 Prolacta Bioscience, Inc. Compositions and methods for treatment of inflammatory and immune diseases
JP2023502260A (ja) * 2019-11-20 2023-01-23 アボット・ラボラトリーズ クロストリジウム・ディフィシル感染症を治療する栄養組成物
CN112870233B (zh) * 2019-11-29 2024-08-23 伊利伊诺科技(上海)有限责任公司 包含乳双歧杆菌与母乳低聚糖的组合物及其应用
CA3161779A1 (en) * 2019-12-19 2021-06-24 An-Katrien VYNCKIER Compositions and methods for managing infections of a urinary tract
US20230149432A1 (en) * 2020-04-03 2023-05-18 Inner Mongolia Yili Industrial Group Co., Ltd. Human Milk Oligosaccharides for Improving Resistance of Organism Against Staphylococcus Aureus Infection
WO2022100758A1 (zh) * 2020-11-16 2022-05-19 内蒙古伊利实业集团股份有限公司 一种含乳双歧杆菌与母乳低聚糖的组合物及其应用
CN116195740A (zh) * 2021-11-30 2023-06-02 内蒙古伊利实业集团股份有限公司 可提升生物体对金黄色葡萄球菌感染抵御能力的益生元与益生菌组合物
CN116195629A (zh) * 2021-11-30 2023-06-02 内蒙古伊利实业集团股份有限公司 婴儿双歧杆菌ylgb-1496在抗衰老、提高先天免疫方面的新应用
KR20250036879A (ko) * 2022-07-15 2025-03-14 디에스엠 아이피 어셋츠 비.브이. Nmn 또는 nad+의 증가에 사용하기 위한 비피도박테리움 및 푸코실화된 hmo의 조합물
AU2023348096A1 (en) * 2022-09-27 2025-02-13 Société des Produits Nestlé S.A. Uses of bifidobacterium longum transitional microorganism
WO2025083288A1 (en) 2023-10-19 2025-04-24 N.V. Nutricia Mixture of human milk oligosaccharides
WO2025083289A1 (en) 2023-10-19 2025-04-24 N.V. Nutricia Mixture of human milk oligosaccharides
WO2025219497A1 (en) 2024-04-19 2025-10-23 Dsm Ip Assets B.V. Combination comprising bifidobacterium bifidum ha-132 and human milk oligosaccharides
WO2025219496A1 (en) 2024-04-19 2025-10-23 Dsm Ip Assets B.V. Nutritional composition comprising bifidobacterium longum ssp. infantis r0033 and human milk oligosaccharides
WO2025256999A1 (en) * 2024-06-11 2025-12-18 Chr. Hansen A/S Composition comprising bifidobacterium longum subsp. infantis and human milk oligosaccharides
CN120000695B (zh) * 2025-02-24 2025-11-04 合生元(广州)健康产品有限公司 2’-岩藻糖基乳糖和益生菌的组合物及其应用和产品

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839281A (en) 1985-04-17 1989-06-13 New England Medical Center Hospitals, Inc. Lactobacillus strains and methods of selection
ES2102485T3 (es) * 1992-07-06 1997-08-01 Nestle Sa Bacteria lactica.
ATE161181T1 (de) 1992-07-06 1998-01-15 Nestle Sa Lactobacillus acidophilus enthaltende antigastritis-mittel
FI104465B (fi) 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
US6045854A (en) 1997-03-31 2000-04-04 Abbott Laboraties Nutritional formulations containing oligosaccharides
WO1999017788A1 (en) * 1997-10-06 1999-04-15 Abbott Laboratories Composition of treatment of candidiasis
US5902743A (en) * 1998-03-20 1999-05-11 Wisconsin Alumni Research Foundation Probiotic bifidobacterium strain
US20020019991A1 (en) * 1998-04-30 2002-02-14 Abbott Laboratories Compositions containing an alpha 1,2-fucose linkage and uses thereof
US6841149B1 (en) * 1998-05-29 2005-01-11 Agri-King, Inc. Probiotic mixture intended for monogastric animals to control intestinal flora populations
EP1034787A1 (en) 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactobacillus strains preventing diarrhea caused by pathogenic bacteria
US7101565B2 (en) * 2002-02-05 2006-09-05 Corpak Medsystems, Inc. Probiotic/prebiotic composition and delivery method
CN1863463B (zh) * 2003-06-23 2011-05-04 雀巢技术公司 用于促进肠道屏障成熟的营养组合物
PL1675481T3 (pl) 2003-10-24 2009-03-31 Nutricia Nv Kompozycja synbiotyczna dla niemowląt
EP1689348B1 (en) 2003-12-05 2013-05-15 Children's Hospital Medical Center Oligosaccharide compositions and use thereof in the treatment of infection
US7137361B2 (en) 2004-06-22 2006-11-21 Federal-Mogul World Wide, Inc. Cylinder head gasket with one-way coolant flow valve
EP1714660A1 (en) 2005-04-21 2006-10-25 N.V. Nutricia Uronic acid and probiotics
EP1776877A1 (en) * 2005-10-21 2007-04-25 N.V. Nutricia Method for stimulating the intestinal flora
EP2388010A1 (en) * 2006-03-10 2011-11-23 N.V. Nutricia Use of non-digestible saccharides for giving an infant the best start after birth
EP2117355B1 (en) 2007-03-13 2017-04-26 N.V. Nutricia Method of improving skills with a composition comprising non-digestible saccharide
US8197872B2 (en) * 2007-05-17 2012-06-12 The Regents Of The University Of California Human milk oligosaccharides to promote growth of beneficial gut bacteria
EP2072052A1 (en) 2007-12-17 2009-06-24 Nestec S.A. Prevention of opportunistic infections in immune-compromised subjects
ES2395838T3 (es) * 2007-12-21 2013-02-15 Compagnie Gervais Danone Método para disminuir el contorno abdominal administrando una bacteria del tipo Bifidobacterium

Also Published As

Publication number Publication date
BRPI0820837A2 (pt) 2015-06-16
WO2009077352A1 (en) 2009-06-25
SG186657A1 (en) 2013-01-30
US9217133B2 (en) 2015-12-22
MY185938A (en) 2021-06-14
US20120308527A1 (en) 2012-12-06
PL2234627T3 (pl) 2016-12-30
IN2010DE04311A (ru) 2010-11-12
EP2234627B1 (en) 2016-05-25
EP2234627A1 (en) 2010-10-06
MX315565B (ru) 2010-09-10
AU2008337646B2 (en) 2014-07-17
PT2234627T (pt) 2016-07-26
EP2072052A1 (en) 2009-06-24
CA2709396A1 (en) 2009-06-25
MX2010006690A (es) 2010-09-10
ES2576642T3 (es) 2016-07-08
AU2008337646A1 (en) 2009-06-25
PH12010501367B1 (en) 2009-06-25
UA102830C2 (ru) 2013-08-27
ZA201005088B (en) 2017-03-27
US20100260720A1 (en) 2010-10-14
RU2486910C2 (ru) 2013-07-10
CN101909644A (zh) 2010-12-08

Similar Documents

Publication Publication Date Title
RU2010129685A (ru) Предупреждение оппортунистических инфекций у индивидуумов с нарушенным иммунитетом
RU2010142003A (ru) Синбиотическая смесь
ES2652464T3 (es) Composiciones que comprenden componentes probióticos y prebióticos y sales minerales, con lactoferrina
RU2010153257A (ru) Пробиотики для улудшения микробиоты пищеварительного тракта
Yen et al. Lactoferrin: an iron-binding antimicrobial protein against Escherichia coli infection
RU2013128570A (ru) Олигосахаридная композиция для лечения острых инфекций дыхательных путей
US11478515B2 (en) Compositions comprising probiotic and prebiotic components and mineral salts, with lactoferrin
RU2008136876A (ru) Применение bifidobacterium longum для предупреждения и лечения воспаления
EP3341001B1 (en) Composition and method for treatment and prophylaxis of intestinal infection and inflammation
Hatakka et al. Probiotics in intestinal and non-intestinal infectious diseases-clinical evidence
RU2011106319A (ru) Пробиотики для увелечения секреции iga у младенцев, рожденных посредством кесарева сечения
RU2017133795A (ru) Композиции для применения в профилактике или лечении инфекций/воспалений в желудочно-кишечном тракте у младенцев или детей младшего возраста
RU2009139657A (ru) Снижение риска диареи
RU2008139598A (ru) Синбиотическая смесь
RU2019139073A (ru) Синергетическая выработка бутирата, связанная со сложностью смеси огм для применения у младенцев или детей младшего возраста в медицинских целях
RU2010123174A (ru) Профилактика и лечение вторичных инфекций после вирусной инфекции
RU2017134672A (ru) Композиции для применения в улучшении консистенции или частоты стула у младенцев или детей младшего возраста
CN105283195A (zh) 用于治疗过敏患者的感染的合生素组合物
JP2012520325A5 (ru)
JP2014512376A (ja) 胃酸過多症の薬理学的処置中に失われる胃のバリア効果を回復させることができるプロバイオティック細菌を含む組成物
RU2009139669A (ru) Синбиотик для улучшения кишечной микробиоты
RU2009100890A (ru) Профилактика и лечение воспаления среднего уха с помощью непатогенных штаммов бактерий
IT201900014388A1 (it) Consorzio di probiotici
WO2014184644A9 (en) Composition comprising lactic acid bacteria and/or bifidobacteria for use in the preventive and/or curative treatment of bacterial infections and/or inflammations of the urinary tract and/or prostate which are the cause of prostatitis and prostatic hypertrophy
RU2019109938A (ru) Питательная композиция для младенцев и/или детей младшего возраста, содержащая олигосахариды

Legal Events

Date Code Title Description
QZ41 Official registration of changes to a registered agreement (patent)

Free format text: LICENCE FORMERLY AGREED ON 20101006

Effective date: 20150710

QC41 Official registration of the termination of the licence agreement or other agreements on the disposal of an exclusive right

Free format text: LICENCE FORMERLY AGREED ON 20101006

Effective date: 20170316

PC43 Official registration of the transfer of the exclusive right without contract for inventions

Effective date: 20190916